Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell Genesys has said that updated data from a phase II trial of its GVAX immunotherapy for prostate cancer showed that patients experienced better survival rates than those who took the current standard of care.
Subscribe to our email newsletter
The study showed that 22 patients who received the immunotherapy had a median survival rate of 35 months. The company previously reported final median survival results from its first multi phase II trial of GVAX immunotherapy for prostate cancer in 34 patients showed an overall median survival of 26.2 months.
The survival results from the two phase II trials compare favorably to the previously published median survival of 18.9 months for prostate cancer patients treated with Taxotere chemotherapy plus prednisone, the current standard of care for these patients. The company's ongoing phase III program is designed to confirm this potential survival benefit for GVAX immunotherapy for prostate cancer.
GVAX immunotherapy for prostate cancer is currently being studied as a single agent and in combination with docetaxel chemotherapy in two phase III clinical trials. Cell Genesys has also received fast track designation for the product.